Saturday 17 October 2026
Export ANNX’s income statement to Excel — free account
Annexon, Inc.
ANNX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 17.7% and free cash flow fell 26.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.41
0.19
−5.28%
Follow ANNX
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 15.33 | 11.34 | 2.06 | 1.57 | 3.86 | 1.29 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 31.94 | 38.01 | 11.95 | 7.65 | 8.40 | 5.66 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 30 | 48 | 61 | 80 | 71 | 100 | 96 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | (19) | (18) | (37) | (63) | (130) | (142) | (134) | (138) | (207) | |||||
| EBT margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | (18) | (37) | (63) | (130) | (142) | (134) | (138) | (207) | |||||
| Depreciation | — | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 2 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | (0.49) | (45.45) | (85.78) | (4.15) | (3.40) | (2.60) | (1.77) | (1.01) | (1.34) | |||||
| Cash flow | — | (0.50) | (42.69) | (65.42) | (3.13) | (2.77) | (2.13) | (1.60) | (0.86) | (1.20) | |||||
| Capex | — | 0.00 | (0.04) | (0.62) | (0.03) | (0.04) | (0.12) | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | (0.50) | (42.73) | (66.03) | (3.16) | (2.81) | (2.25) | (1.60) | (0.86) | (1.20) | |||||
| Book value | — | (1.21) | (159.43) | (231.73) | 20.30 | 6.05 | 4.23 | 3.31 | 2.13 | 1.36 | |||||
| Shares, m | — | 38 | 0 | 0 | 17 | 38 | 55 | 76 | 137 | 155 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | (19) | (17) | (28) | (53) | (106) | (116) | (121) | (118) | (186) | ||||
| Capex | — | (1) | 0 | 0 | 0 | (2) | (7) | 0 | 0 | 0 | |||||
| Free cash flow | — | (19) | (17) | (29) | (54) | (108) | (123) | (121) | (118) | (186) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | 2 | 42 | 40 | 343 | 226 | 226 | 246 | 286 | 200 | ||||
| Total debt | — | 49 | 107 | — | — | 35 | 33 | — | — | — | |||||
| Net debt | — | 46 | (44) | (44) | (351) | (243) | (243) | (260) | (312) | (238) | |||||
| Shareholders’ equity | — | (46) | (64) | (100) | 344 | 232 | 231 | 251 | 293 | 212 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | (67.16) | (76.76) | (78.08) | (34.66) | (40.54) | (49.62) | (46.07) | (42.67) | (66.45) | ||||
| ROIC | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | 34.04 | 33.47 | 46.49 | (57.69) | (45.24) | (61.30) | (55.73) | (50.84) | (82.63) | |||||
Negative figures in brackets.
Charts ten years each
Annexon, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ANL Adlai Nortye Ltd. Sponsored ADR | $710.1M | — | — | — | — | +46.03% (above 0%: growing) | — | — | Compare |
| OABI OmniAb, Inc. | $687.7M | — (loss-making) | — (loss-making) | +244.24% (above 0%: growing) | n/m | +211.16% (above 0%: growing) | 95.45% | (49.47%) | Compare |
| ANNX Annexon, Inc. | $682.5M | — (loss-making) | — | — | n/m | −26.41% (below 0%: shrinking) | 0.00% | 0.00% | |
| MDXG MiMedx Group, Inc | $682.2M | 111× | — (loss-making) | −34.73% (below 0%: shrinking) | n/m | −174.83% (below 0%: shrinking) | 68.96% | (28.69%) | Compare |
| CADL Candel Therapeutics, Inc. | $681.8M | — (loss-making) | — (loss-making) | 0.00% | n/m | −93.35% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PHAR Pharming Group N.V. Sponsored ADR | $681.6M | 62.4× | — (loss-making) | −3.22% (below 0%: shrinking) | −57.14% (below 0%: shrinking) | −183.87% (below 0%: shrinking) | 83.92% | 1.44% | Compare |
| GYRE Gyre Therapeutics, Inc. | $678.6M | — (loss-making) | — (loss-making) | −2.12% (below 0%: shrinking) | n/m | −130.45% (below 0%: shrinking) | 92.41% | (49.35%) | Compare |
| AURA Aura Biosciences, Inc. | $657.5M | — (loss-making) | — | — | n/m | −56.26% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| DSGN Design Therapeutics, Inc. | $655.9M | — (loss-making) | — (loss-making) | — | n/m | −7.00% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $681.7M | — | — | −2.12% | — | −74.80% | 68.96% | 0.00% |
Annexon, Inc. (ANNX) key facts
- Concern: Annexon, Inc. reported a net loss of $206.7 million, or a loss of $1.34 per share, for fiscal 2025.
- Annexon, Inc. (ANNX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, ANNX traded at $3.41, a market capitalization of $682.5 million.
- Return on equity was −82.6% and debt-to-equity 0.00.
Annexon, Inc. (ANNX) Latest News
No news at this impact. Lower the threshold for more.